Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Non-Current Deffered Revenue (2016 - 2020)

Historic Non-Current Deffered Revenue for Agios Pharmaceuticals (AGIO) over the last 9 years, with Q2 2020 value amounting to $491000.0.

  • Agios Pharmaceuticals' Non-Current Deffered Revenue fell 9904.87% to $491000.0 in Q2 2020 from the same period last year, while for Jun 2020 it was $491000.0, marking a year-over-year decrease of 9904.87%. This contributed to the annual value of $50.6 million for FY2019, which is 1543.08% down from last year.
  • Agios Pharmaceuticals' Non-Current Deffered Revenue amounted to $491000.0 in Q2 2020, which was down 9904.87% from $571000.0 recorded in Q1 2020.
  • In the past 5 years, Agios Pharmaceuticals' Non-Current Deffered Revenue registered a high of $183.5 million during Q2 2016, and its lowest value of $491000.0 during Q2 2020.
  • Moreover, its 5-year median value for Non-Current Deffered Revenue was $69.4 million (2018), whereas its average is $87.2 million.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Non-Current Deffered Revenue surged by 107420.51% in 2016, and later tumbled by 9904.87% in 2020.
  • Over the past 5 years, Agios Pharmaceuticals' Non-Current Deffered Revenue (Quarter) stood at $154.3 million in 2016, then fell by 18.47% to $125.8 million in 2017, then tumbled by 52.46% to $59.8 million in 2018, then dropped by 15.43% to $50.6 million in 2019, then crashed by 99.03% to $491000.0 in 2020.
  • Its Non-Current Deffered Revenue was $491000.0 in Q2 2020, compared to $571000.0 in Q1 2020 and $50.6 million in Q4 2019.